Table 3.

Objective response rate, progression-free survival, and overall survival outcomes

Effectiveness outcome	All patients (n = 48)	Papillary RCC (n = 24)	Chromophobe RCC (n = 9)
Response rate (RECIST 1.1), n (%)
Partial responses	13 (27.1)	6 (25.0)	2 (22.2)
Complete responses	0 (0.0)	0 (0.0)	0 (0.0)
Stable disease	27 (56.3)	14 (58.3)	5 (55.5)
Progressions of disease	6 (12.5)	3 (12.5)	1 (11.1)
Not evaluable	2 (4.2)	1 (4.2)	1 (11.1)
Disease control rate	40 (83.3)	20 (83.3)	7 (77.8)
PFS
Median (mo) (95%CI)	12.3 (3.6-20.9)	-	-
Rate of patients progression free at 6 mo	67.8%	-	-
Rate of patients progression free at 12 mo	49.0%	-	-
OS
Median (mo) (95%CI)	27.6 (18.3-37.1)	-	-
Rate of patients alive at 12 mo	82.7%	-	-
Rate of patients alive at 24 mo	62.0%	-	-

RCC: Renal cell carcinoma; PFS: Progression free survival; OS: Overall survival; RECIST 1.1: Response Evaluation Criteria in Solid Tumours version 1.1.